One Shot, Double the Protection: A Combined COVID-19 and Flu Vaccine Could Be a Game-Changer for Seniors

Every fall, millions of Americans — especially older adults — navigate the same annual ritual: scheduling a flu shot, then separately booking a COVID-19 vaccine appointment, making two trips, waiting in two lines, and rolling up their sleeve twice. It’s a routine that, for many seniors, creates enough friction to result in skipping one or both vaccines entirely. In a country where flu and COVID-19 together contribute to hundreds of thousands of hospitalizations every single year, that missed protection carries real consequences.

But what if all of that changed with a single injection?

A new era in vaccination may be closer than you think. Researchers and major pharmaceutical companies are actively developing combination vaccines designed to protect against both seasonal influenza and COVID-19 in one dose — and the science behind them is not only feasible, it’s increasingly showing that this approach may actually be more effective than receiving the two shots separately. For seniors and their families, this innovation could transform what it means to stay protected during respiratory virus season.

The Problem:
Two Dangerous Viruses, Two Separate Appointments

To understand why a combined vaccine matters so much, it helps to look at the challenge we’re currently managing, and why our current approach isn’t working as well as it should.

Seasonal influenza and COVID-19 are both highly contagious respiratory illnesses that tend to surge during the fall and winter months in the United States. Both viruses mutate over time, which is why health experts update vaccines for each illness annually to match the strains most likely to circulate in any given season. And both viruses pose disproportionately severe risks for adults aged 65 and older, whose immune systems are less equipped to mount strong responses to new infections.

Despite this well-documented risk, vaccination rates among seniors remain stubbornly lower than public health targets. The reasons are varied, but one of the most frequently cited barriers is simply inconvenience. For older adults managing chronic conditions, mobility limitations, or transportation challenges, the prospect of coordinating two separate medical appointments — often weeks apart — is a meaningful obstacle. Add in the time cost of arranging caregiving support, the fatigue of repeated clinic visits, and the cognitive load of tracking two different vaccine schedules, and it becomes clear why some people fall through the cracks.

The solution, when you step back and look at it, seems almost obvious: combine the two vaccines into one.

What the Science Says:
A Combination Vaccine Can Actually Outperform

The concept of combination vaccines is not new. Vaccines that protect against multiple diseases in a single shot have been a cornerstone of pediatric medicine for decades, for example the DTaP shot, which covers diphtheria, tetanus, and pertussis in one injection. Applying this same logic to flu and COVID-19 is a natural extension of a well-established principle.

That finding deserves emphasis: participants who received the single combined shot ended up with stronger immune responses than those who received both shots individually. This is not merely a convenience story — it is a compelling scientific case for a better approach to annual respiratory virus vaccination.

Novavax, another major vaccine developer, has also entered the combination vaccine race. Their protein-based COVID-Influenza Combination (CIC) vaccine candidate completed an initial Phase 3 cohort in 2025 and showed immune responses comparable to existing licensed vaccines for both viruses, with a favorable safety profile. The fact that multiple companies are using different vaccine technologies and independently arriving at safe, effective combination candidates speaks to the robustness of this approach.

The Hidden Danger:
When Flu and COVID-19 Strike Together

One of the most compelling and least discussed arguments for a combination vaccine is the risk of co-infection: being infected with both influenza and COVID-19 at the same time.

Research published in peer-reviewed immunology journals has found that simultaneous flu and COVID-19 infection is significantly more dangerous than either illness alone. Animal studies have shown that co-infection leads to more severe pneumonia and pulmonary damage, prolonged acute illness, elevated inflammatory responses, and in some cases dramatically higher mortality rates compared to single-virus infection. Clinical observational data in humans has corroborated these findings, demonstrating worse outcomes in patients hospitalized with both viruses concurrently.

A vaccine that builds strong immunity against both viruses simultaneously doesn’t just eliminate two inconveniences. It closes a dangerous gap that exists when a person is protected against one virus but not the other and in a season when both are circulating, that gap is very real.

The Bigger Picture:
What a Combo Vaccine Could Mean for Public Health

The benefits of a combined COVID-flu vaccine extend well beyond the individual level. From a public health and healthcare economics perspective, this innovation could reshape how we approach annual respiratory virus prevention at scale.

Dramatically Higher Vaccination Uptake

Survey data shows that the majority of American consumers and healthcare providers say they would be more likely to get vaccinated if a combined shot were available rather than two separate injections. In public health, eliminating barriers, even small ones, can have an outsized impact on coverage rates. Higher uptake means broader population immunity and fewer opportunities for the virus to circulate and mutate.

Reduced Burden on Healthcare Infrastructure

Each vaccination appointment requires clinical staff time, scheduling capacity, cold-chain storage, documentation, and billing resources. A combination vaccine effectively cuts all of that in half during the fall vaccination push which is one of the busiest periods of the year for pharmacies and primary care practices. For an already-strained healthcare system, that efficiency gain is not trivial.

Equity and Access Improvements

For underserved communities including low-income seniors, those in rural areas with limited healthcare access, and individuals with disabilities, the practical barriers to multiple clinic visits are even more pronounced. A single-visit vaccination protocol is inherently more equitable, making it more likely that those with the least access are still protected.

Streamlined Global Vaccination Campaigns

In the context of international public health, a combination vaccine that covers two major respiratory threats simultaneously could simplify vaccination programs in lower-resource settings where cold-chain logistics and healthcare worker capacity are constrained.

The Road Ahead:
Where Development Stands Today

The combination COVID-flu vaccine is not yet available at your local pharmacy — but the path to approval is well underway and moving quickly.

Moderna’s mRNA-based combination candidate (mRNA-1073) has completed large-scale Phase 3 trials with results published in JAMA, and the company has signaled that regulatory submission is in progress, with potential approval targeted for 2026. The FDA has indicated it requires additional efficacy data before approving the combination shot, a standard step in the regulatory process that reflects the agency’s commitment to safety, not a setback for the underlying science.

Novavax’s protein-based combination candidate has completed its initial Phase 3 cohort with encouraging immunogenicity data and is pursuing further development and partnership opportunities . Having multiple companies advancing different technologies toward the same goal adds resilience to the pipeline and increases the likelihood that approved options will be available across different patient populations and healthcare settings.

Once approved, the combination vaccine is widely expected to become a standard part of the annual fall vaccination calendar — as familiar and routine as the current flu shot, but delivering twice the protection in a single visit.

What Seniors Can Do Right Now

While the combination vaccine works through the final stages of clinical and regulatory review, there are steps older adults can take today to stay protected:

1. Get both your current flu and COVID-19 vaccines this season. The good news is that today’s vaccines can be administered at the same appointment, one shot in each arm, and health experts confirm that co-administration is safe and effective.
2. Talk to your doctor or pharmacist about your individual risk profile and which vaccines are recommended for you, including RSV vaccination if you are 60 or older.
3. Stay informed about combination vaccine approval timelines so you can plan for a simplified vaccination experience as soon as the option becomes available.
4. Encourage family members and friends to get vaccinated — community immunity protects everyone, especially the most vulnerable.

In Conclusion:
The Bottom Line

The annual flu shot and COVID-19 vaccine are two of the most important tools older adults have to stay healthy, independent, and out of the hospital. A combination vaccine that delivers both in a single dose is not just a convenience, it’s a smarter, more efficient, and potentially more effective approach to respiratory virus protection backed by real clinical data and significant scientific investment.

The research is strong. The trials are promising. The regulatory pathway is in motion. And for the millions of seniors who deserve easier, more powerful access to the protection they need, a simpler future may be just around the corner.

One shot. Two protections. A healthier, easier tomorrow.

Complete the Questionnaire Below
to Send Your Information for Current or Future Studies

When accepted for a study you may receive compensation for inconvenience and travel!